对质瘤中聚胺代谢相关基因的综合分析:对预后和治疗的影响
Yujia Zhao1,2, Zhenkai Fu3, Sijie Chen2
1Department of Oncology, Tangdu Hospital, the Fourth Military Medical University, Xi'an, Shaanxi, China.
Frontiers in oncology
|August 5, 2025
概括
一个新的11基因质瘤风险模型通过分析聚胺代谢相关基因 (PMRGs) 有效预测预后. 该模型识别了具有较差结果和免疫抑制微环境的高风险患者,并突出了PMRGs作为治疗目标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 瘤进展涉及失调的聚胺代谢.
- 多氨酸对癌细胞生长和存活至关重要.
- 基于聚胺代谢相关基因 (PMRGs) 的质瘤存在很少的预后模型.
研究的目的:
- 根据PMRGs开发和验证基于质瘤的预后风险模型.
- 研究PMRG风险亚型与瘤免疫微环境之间的关系.
- 确定质瘤潜在治疗向的关键PMRGs.
主要方法:
- 利用37个PMRG的TCGA,CGGA和GEO数据库中的mRNA表达数据.
- 使用LASSO-Cox回归构建了一个11基因风险模型.
- 分析了瘤免疫微环境,药物敏感性,并在质瘤组织和通过单细胞RNA测序验证了关键基因.
主要成果:
- 开发了一种11个基因的风险模型,将质瘤患者分为高风险和低风险亚型.
- 高风险亚型与预后较差,免疫抑制微环境和独特的免疫特征相关.
- 鉴定了精子合成酶 (SMS) 作为一个关键的PMRG,在质瘤瘤中显著增加表达.
结论:
- 与PMRG相关的风险模型作为质瘤的可靠预后生物标志物.
- 准聚胺代谢是一种有前途的治疗策略,用于质瘤治疗.
更多相关视频
06:32Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
8.0K
09:17Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma
Published on: September 13, 2022
2.4K
相关概念视频
Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
